2-Amino-5-(3-methoxy-4-prop-2-enoxyphenyl)-1,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-4,7-dione | 878437-15-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-Amino-5-(3-methoxy-4-prop-2-enoxyphenyl)-1,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-4,7-dione
• 英文别名: 2-amino-5-(3-methoxy-4-prop-2-enoxyphenyl)-3,5,6,8-tetrahydropyrido[2,3-d]pyrimidine-4,7-dione
• CAS: 878437-15-1
• 化学式: C₁₇H₁₈N₄O₄
• 分子量: 342.35
• InChiKey: DCSWTWUTSKSXOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• ANALGESIC DRUG USING PAC1 RECEPTOR ANTAGONISTIC DRUG
  申请人：KAGOSHIMA UNIVERSITY

  公开号：US20210188841A1

  公开（公告）日：2021-06-24

  This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R 1 is a C 1-6 -alkoxy group or a C 1-6 -haloalkoxy group; R 2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.

  本发明涉及一种镇痛药物，包含下式（I）或（II）所表示的化合物，其中R1为C1-6-烷氧基或C1-6-卤代烷氧基；R2为氢原子；R为取代有卤素原子的吲唑基；取代或未取代的苯基；吡唑基；或取代或未取代的芳基烷基；或其盐或溶剂化物。
• Analgesic drug using PAC1 receptor antagonistic drug
  申请人：KAGOSHIMA UNIVERSITY

  公开号：US11365194B2

  公开（公告）日：2022-06-21

  This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.

  本发明涉及一种镇痛药物，它由下式（I）或（II）所代表的化合物组成，其中 R1 是 C1-6 烷氧基或 C1-6 卤烷氧基；R2 是氢原子；R 是被卤原子取代的吲唑基；取代或未取代的苯基；吡唑基；或取代或未取代的芳烷基；或其盐，或其溶液。
• ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST
  申请人：KAGOSHIMA UNIVERSITY

  公开号：US20220184081A1

  公开（公告）日：2022-06-16

  This invention relates to an antipruritic agent of formula (I) or (II), wherein R 1 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group; R 2 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.